1. Home
  2. RDY vs BLTE Comparison

RDY vs BLTE Comparison

Compare RDY & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDY
  • BLTE
  • Stock Information
  • Founded
  • RDY 1984
  • BLTE 2018
  • Country
  • RDY India
  • BLTE United States
  • Employees
  • RDY N/A
  • BLTE 25
  • Industry
  • RDY Biotechnology: Pharmaceutical Preparations
  • BLTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDY Health Care
  • BLTE Health Care
  • Exchange
  • RDY Nasdaq
  • BLTE Nasdaq
  • Market Cap
  • RDY 2.1B
  • BLTE 1.8B
  • IPO Year
  • RDY N/A
  • BLTE 2022
  • Fundamental
  • Price
  • RDY $13.94
  • BLTE $59.04
  • Analyst Decision
  • RDY Buy
  • BLTE Strong Buy
  • Analyst Count
  • RDY 1
  • BLTE 4
  • Target Price
  • RDY $17.00
  • BLTE $96.67
  • AVG Volume (30 Days)
  • RDY 2.9M
  • BLTE 39.1K
  • Earning Date
  • RDY 05-06-2025
  • BLTE 05-12-2025
  • Dividend Yield
  • RDY 3.50%
  • BLTE N/A
  • EPS Growth
  • RDY 2.68
  • BLTE N/A
  • EPS
  • RDY 0.75
  • BLTE N/A
  • Revenue
  • RDY $3,637,607,642.00
  • BLTE N/A
  • Revenue This Year
  • RDY $17.23
  • BLTE N/A
  • Revenue Next Year
  • RDY $9.19
  • BLTE N/A
  • P/E Ratio
  • RDY $18.46
  • BLTE N/A
  • Revenue Growth
  • RDY 14.74
  • BLTE N/A
  • 52 Week Low
  • RDY $12.26
  • BLTE $35.00
  • 52 Week High
  • RDY $16.89
  • BLTE $86.53
  • Technical
  • Relative Strength Index (RSI)
  • RDY 62.08
  • BLTE 45.81
  • Support Level
  • RDY $13.59
  • BLTE $53.60
  • Resistance Level
  • RDY $13.04
  • BLTE $59.13
  • Average True Range (ATR)
  • RDY 0.36
  • BLTE 3.81
  • MACD
  • RDY 0.11
  • BLTE -0.01
  • Stochastic Oscillator
  • RDY 97.78
  • BLTE 60.52

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Share on Social Networks: